Drugs / MAGALDRATE ANHYDROUS
last change May 2026 re-read 2 minutes ago

MAGALDRATE ANHYDROUS

Small molecule

Developed for
gastroesophageal reflux disease
Investigated by
Tecnoquimicas · Valenta Pharm JSC

Trials 2 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT06367452 Oct 2023 → Jan 2024 Tecnoquimicas Completed No outcome recorded
Phase not applicable1 trial
NCT06552624 Jul 2021 → Aug 2022 active peptic ulcer disease, dyspepsia, upper digestive tract disorder Valenta Pharm JSC Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT07611162 Comparator May 2026 → May 2030 expected gastroesophageal reflux disease University of Mons Not yet recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as MAGALDRATE ANHYDROUS ChEMBL registry synonym — accepted as the source's own label CHEMBL3833408
Known as AY-5710 ChEMBL registry synonym — accepted as the source's own label CHEMBL3833408
Known as Magaldrate ClinicalTrials.gov intervention name — accepted as the source's own label NCT06367452
2

NCT06552624

NCT07611162

Known as Magaldrato ChEMBL registry synonym — accepted as the source's own label CHEMBL3833408
Known as Magnesium aluminate hydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL3833408
Known as Monalium hydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL3833408
Known as Riopan ChEMBL registry synonym — accepted as the source's own label CHEMBL3833408
Modality Small molecule CHEMBL3833408